4,285,365 Shares in Veru Inc. (NASDAQ:VERU) Acquired by MPM Bioimpact LLC

MPM Bioimpact LLC purchased a new stake in Veru Inc. (NASDAQ:VERU - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,285,365 shares of the company's stock, valued at approximately $2,788,000. MPM Bioimpact LLC owned approximately 2.93% of Veru at the end of the most recent quarter.A number of other hedge funds and other institutional investors have also recently modified their holdings of VERU. Cetera Investment Advisers raised its holdings in Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after purchasing an additional 19,724 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Veru by 17.5% in the 4th quarter. Bank of America Corp DE now owns 217,792 shares of the company's stock worth $142,000 after purchasing an additional 32,447 shares during the period. Jane Street Group LLC grew its stake in shares of Veru by 35.2% during the 4th quarter. Jane Street Group LLC now owns 130,406 shares of the company's stock worth $85,000 after acquiring an additional 33,952 shares during the period. Integrated Wealth Concepts LLC grew its stake in Veru by 31.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock valued at $56,000 after buying an additional 20,500 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Veru by 2,500.0% during the 4th quarter. NewEdge Advisors LLC now owns 130,000 shares of the company's stock valued at $85,000 after purchasing an additional 125,000 shares during the period. Institutional investors own 47.16% of the company's stock. Veru Stock PerformanceNASDAQ:VERU opened at $0.52 on Wednesday. Veru Inc. has a 52-week low of $0.45 and a 52-week high of $1.57. The firm has a market capitalization of $75.48 million, a price-to-earnings ratio of -1.98 and a beta of -0.74. The stock has a fifty day moving average of $0.53 and a 200 day moving average of $0.63. Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. Equities analysts forecast that Veru Inc. will post -0.22 earnings per share for the current fiscal year. Insider Transactions at VeruIn other Veru news, Director Michael L. Rankowitz purchased 95,279 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $0.55 per share, with a total value of $52,403.45. Following the acquisition, the director now owns 195,279 shares in the company, valued at approximately $107,403.45. This trade represents a 95.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 14.90% of the company's stock. Veru Profile (Free Report)Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.Featured ArticlesFive stocks we like better than VeruHigh Dividend REITs: Are They an Ideal Way to Diversify?Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreWhat Are Earnings Reports?AppLovin Surges on Earnings: What's Next for This Tech Standout?Procter & Gamble NYSE: PG Pulls Back After Shaky GuidanceU.S. Regulators Target CrowdStrike: Is It a Signal or Noise? This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Veru Right Now?Before you consider Veru, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here